Regulators with the U.S. Food and Drug Administration (FDA) on Aug. 21 approved the first vaccine to be taken by pregnant women to prevent respiratory syncytial virus (RSV) infections in babies and toddlers.
Pfizer’s Abrysvo vaccine, a first-of-its-kind single-dose injection administered into the muscle, was approved for use at 32 through 36 weeks of pregnancy.
